+1 more
Substituted phenethylamineamphetamine, methamphetamine, mephedrone +3 moreamphetamine, methamphetamine, mephedrone, cocaine, methylphenidate, MDMA show less
3-MMC
3-methyl-N-methylcathinone
3-MMC (3-methylmethcathinone) — metaphedrone — is a synthetic stimulant of the substituted cathinone class. It is a positional isomer of mephedrone, differing by a single atom's placement on the phenyl ring. It forces dopamine and norepinephrine release,[1] making it a stimulant first and an empathogen second.
3-MMC (3-methylmethcathinone) — metaphedrone — is a synthetic stimulant of the substituted cathinone class. It is a positional isomer of mephedrone with a more stimulant-dominant profile.[1] 3-MMC is a triple monoamine releasing agent, producing its effects by forcing catecholamine-dominant neurotransmitter release.[2]
+1 more
Substituted phenethylamineamphetamine, methamphetamine, mephedrone +3 moreamphetamine, methamphetamine, mephedrone, cocaine, methylphenidate, MDMA show less
3-MMC entered the European drug market in Sweden in 2012, engineered to evade mephedrone's scheduling through a single ring-position change.[2] It spread rapidly; by 2021 it was the most prevalent new psychoactive substance in European wastewater surveillance.[3] It is now internationally scheduled under the Convention on Psychotropic Substances and controlled in most major jurisdictions.
Subjective effects include psychostimulation, mood elevation, empathy enhancement, information processing enhancement, and mild dissociation. Social settings draw out sociability and warmth; solitary use foregrounds raw stimulant drive.[4] Compulsive redose, jaw tension, elevated heart rate, and anxious agitation are the most reported unwanted effects.[5]
Dependence liability is high — animal models match methamphetamine[6] and compulsive within-session redosing is well documented.[5] Short duration and strong dopamine reinforcement drive dose escalation; liver toxicity at human-relevant doses[7] and 27 confirmed deaths by 2021[8] define the acute risk. The first controlled human study appeared in 2025[4] — most of the risk profile rests on animal data, case reports, and pharmacological analogy.
History[edit]
History
Discovery
Swedish drug authorities first flagged 3-MMC through the EU Early Warning System in 2012.[9] Moving mephedrone's ring methyl from position 4 to position 3 was enough to produce a new legal stimulant with nearly identical effects.[2] One-atom adjustments that bypassed existing law became the defining strategy of cathinone producers that decade.[10]
Market expansion
Chinese factories supplied the market until precursor controls tightened in 2019–2020. Production moved to India; a single seizure of Indian-sourced material in 2021 recovered 1,500 kg of combined 3-MMC and 3-CMC.[8] Twelve cities' wastewater data that year ranked 3-MMC as the most prevalent novel psychoactive in Europe.[3]
Scheduling and modern research
A November 2021 risk assessment linking 3-MMC to 27 deaths prompted a March 2022 EU-wide ban.[8] The WHO added it to international Schedule II in 2023.[2] Human pharmacology wasn't tested in controlled trials until 2025 — well over a decade into its widespread use.[4][11]
Metaphedrone is named for the meta-ring position — the feature that distinguishes it structurally from mephedrone's para-substitution. The name sees little use in practice; the compound trades almost entirely as 3-MMC. User culture frames it as the functional isomer: more suited to work and stimulation, less to emotional connection — a split the receptor pharmacology broadly supports.[1]
Chemistry[edit]
Chemistry
Structural identity
3-MMC belongs to the substituted cathinone family — synthetic compounds built on the β-keto amphetamine scaffold found naturally in the khat plant (Catha edulis). Its molecular formula is C₁₁H₁₅NO (molecular weight 177.24 g/mol).[12] It is a direct positional isomer of mephedrone (4-MMC) — both share the same atomic formula but place the ring methyl group at different positions.
That single positional difference changes the pharmacological profile substantially: 3-MMC releases dopamine and norepinephrine roughly 10 times more potently than serotonin, while mephedrone releases all three less selectively.[1][13] This catecholamine dominance is why 3-MMC reads more as a stimulant than an empathogen.
Pharmacology[edit]
Pharmacology
Mechanism of action
3-MMC enters dopamine, norepinephrine, and serotonin transporters and forces neurotransmitter release into the synapse[1] — the same mechanism as amphetamines. Dopamine and norepinephrine are released roughly 10 times more potently than serotonin,[1] placing 3-MMC closer to amphetamine than MDMA on the stimulant–entactogen spectrum.[13] Unlike classical amphetamines, 3-MMC does not activate TAAR1[14] — a receptor that normally brakes dopamine release.
Pharmacokinetics
No formal pharmacokinetic study has been published for 3-MMC. The first controlled trial showed effects peaking around 1 hour after oral dosing and resolving within 5 hours.[4][11]
Metabolism
The liver enzymes CYP2D6 and CYP2E1 process 3-MMC into metabolites — blocking either reduced drug-induced cell death in rat liver cells, indicating both generate toxic byproducts.[7] Three primary metabolites have been confirmed in human samples;[15] broader profiling found 25 Phase I metabolites in the laboratory.[16] Related cathinones follow similar metabolic pathways.[17]
Neuroscience[edit]
Neuroscience
Where it acts
3-MMC's primary target is the mesolimbic dopamine pathway — the reward circuit running from the ventral tegmental area to the nucleus accumbens. Dopamine flooding this circuit drives acute euphoria and reinforcement. At reward-conditioning doses, 3-MMC activates this pathway more intensely than methamphetamine,[6] suggesting unusually strong engagement of the brain's reward system.
Norepinephrine release drives the sympathomimetic — elevated heart rate, raised blood pressure, and the cognitive improvements observed in clinical testing.[4]
Why it matters
Chronic use selectively weakens inhibitory signaling in the nucleus accumbens without affecting excitatory transmission.[6] The reward circuit's brake weakens while the accelerator stays intact. This predicts a tilt toward compulsive drug-seeking[5] — consistent with the compulsive redose widely reported by users.
Whether 3-MMC produces the kind of serotonin nerve-cell damage documented for MDMA and methamphetamine has not been tested. The source of its analgesic effects[11] — whether noradrenergic, serotonergic, or dopaminergic — is uncharacterized. The absence of TAAR1 activation[14] removes a brake on dopamine release that classical amphetamines retain; whether this produces an unrestrained dopamine response remains untested.
Subjective Effects[edit]
3-MMC occupies a middle ground between stimulant drive and warmth. The experience has a clean, functional quality — sharpened focus, raised energy, and notable information processing enhancement.[4] Setting shapes its character: social environments draw out sociability and warmth; solitary use foregrounds raw stimulant drive.
3-MMC sits between amphetamine and mephedrone — more stimulant-dominant than mephedrone, less purely empathogenic than MDMA.[4][18] It is not a psychedelic and does not produce the perceptual or emotional weight of a classical hallucinogen — the experience stays grounded and social.
3-MMC first appeared on the European drug market in Sweden in 2012, exploiting a single-atom structural difference from already-banned mephedrone.[3] By 2021 it had become the most prevalent new psychoactive substance in European wastewater surveillance.[4] It is now internationally scheduled under the Convention on Psychotropic Substances (Schedule II, 2023) and controlled in most major jurisdictions.
Subjective effects include psychostimulation, mood elevation, empathy enhancement, information processing enhancement, and mild dissociation. The experience sits between amphetamine-like stimulation and mephedrone-like entactogenic warmth — social settings draw out the empathogenic dimension, while solitary use emphasizes raw cognitive drive.[5] Compulsive redosing, jaw tension, increased heart rate, and anxious agitation are characteristic unsought effects.[6]
Dependence liability is high — animal models show reward conditioning comparable to methamphetamine,[7] and compulsive redosing is widely documented.[6] Short duration and strong dopamine reinforcement drive within-session dose escalation; liver toxicity at human-relevant concentrations[8] and 27 deaths documented by November 2021[9] define the acute risk. The first controlled human study appeared in 2025[5] — most of the safety profile rests on animal data, case reports, and pharmacological analogy.
History[edit]
History
Discovery
3-MMC entered the European drug market in Sweden in 2012, identified through the EU Early Warning System.[10] The compound was a calculated market response to mephedrone scheduling — by shifting a single methyl group from the 4-position to the 3-position on the phenyl ring, manufacturers produced a functionally similar stimulant that fell outside existing controls.[3] This cat-and-mouse dynamic between novel psychoactive substance producers and drug control legislators defined the synthetic cathinone class throughout the 2010s.[11]
Market expansion
3-MMC spread rapidly across Europe, constituting 22% of all NPS seizures in Italian forensic laboratories between 2013 and 2015.[12] Supply initially flowed from Chinese manufacturers, but following Chinese precursor controls in 2019–2020, large-scale production shifted to India — European authorities seized 1,500 kg of combined 3-MMC and 3-CMC from Indian sources in 2021.[9] By that year, wastewater monitoring across 12 European cities confirmed 3-MMC as the most prevalent new psychoactive substance in circulation.[4]
Scheduling and modern research
The EMCDDA's November 2021 risk assessment, documenting 27 deaths and life-threatening health consequences, triggered EU-wide control in March 2022.[9] The WHO recommended international Schedule II placement in 2023.[3] The first controlled human pharmacology studies appeared in 2025 — more than a decade after the compound entered human use.[5][13] Policy concern now centers on substitution: the Netherlands' 2024 reclassification of 3-MMC to harddrug status may push users toward less-characterized analogues such as 2-MMC and 3-CMC.[6]
The name metaphedrone reflects the compound's meta-substitution pattern on the phenyl ring, distinguishing it from mephedrone's para-substitution. In practice, 3-MMC circulates under its alphanumeric abbreviation rather than any established street name. User communities describe it as a more functional mephedrone — stimulant-dominant where mephedrone is empathogenic — a reputation that maps loosely onto the actual receptor selectivity differences between the two isomers.[2]
Chemistry[edit]
Chemistry
Structural identity
3-MMC belongs to the substituted cathinone family — synthetic compounds built on the β-keto amphetamine backbone found naturally in the khat plant (Catha edulis). Its full chemical name is 2-(methylamino)-1-(3-methylphenyl)propan-1-one: a propiophenone core carrying a methyl group at the 3-position of the phenyl ring and an N-methyl group on the amino nitrogen.[14]
The compound is a direct positional isomer of mephedrone (4-MMC), differing only in where the ring methyl sits — meta versus para. This single-atom shift substantially changes the pharmacological profile: 3-MMC shows roughly 10-fold selectivity for catecholamine transporters over serotonin, while mephedrone releases monoamines less selectively.[2] The beta-keto group that defines cathinones reduces blood-brain barrier penetration compared to the equivalent amphetamine structure.
| Molecular formula | C₁₁H₁₅NO |
| Molecular weight | 177.24 g/mol |
Stereochemistry
3-MMC has one chirality center at the alpha-carbon, producing two mirror-image forms (R and S). All known synthesis routes yield the racemic mixture. No study has separated and tested the individual enantiomers of 3-MMC — a notable gap, since for the related mephedrone the R-enantiomer produces stronger rewarding effects in animals.citation needed
Physical properties
The hydrochloride salt is a white crystalline powder.[14] No published melting point, solubility, or stability data exist — a basic characterization gap unusual for a compound this widely used.
Pharmacology[edit]
Pharmacology
Mechanism of action
3-MMC enters the dopamine, norepinephrine, and serotonin transporters as a substrate and forces neurotransmitter release into the synapse — a mechanism shared with amphetamines and other cathinones.[2] The defining feature is selectivity: 3-MMC releases dopamine and norepinephrine roughly 10 times more potently than serotonin.[2] This catecholamine-dominant profile places it closer to amphetamine than to MDMA on the stimulant–entactogen spectrum.[1]
At higher concentrations, 3-MMC also blocks monoamine reuptake, but the releasing mechanism dominates at doses people actually take.[2][15] The compound also binds serotonin and adrenergic receptors as secondary targets, though the significance of these interactions at recreational doses remains unclear.[15]
Unlike classical amphetamines, 3-MMC does not activate TAAR1 (TAAR1).[16] TAAR1 normally acts as a brake on dopamine signaling — its absence may contribute to 3-MMC's pronounced reinforcing properties.
Pharmacokinetics
No formal human pharmacokinetic study has measured absorption rate, peak blood levels, half-life, or bioavailability for 3-MMC by any route. The best available timing data come from the first controlled trial, where cardiovascular and cognitive effects peaked at roughly 1 hour after oral dosing and resolved within 5 hours.[5] Analgesic effects followed a similar time course.[13]
Blood concentrations from case reports — 800 ng/mL in a fatal single-substance case,[17] 177 ng/mL in a non-fatal chemsex intoxication[18] — provide isolated reference points but no systematic dose-concentration relationship. No correlation between blood levels and intoxication severity has been established.[19]
Metabolism
Three primary metabolites have been confirmed in human samples (plasma, urine, saliva, hair): a keto-reduced form, an N-desmethyl form, and a hydroxylated form, with at least one present in 61% of analyzed samples.[20] Broader in vitro profiling identified 25 Phase I metabolites using human liver microsomes.[21]
The liver enzymes CYP2D6 and CYP2E1 are involved in 3-MMC metabolism — blocking either enzyme reduced drug-induced cell death in rat liver cells, indicating both produce toxic metabolic byproducts.[8] inferred The precise contribution of each enzyme to overall clearance in humans has not been determined. Related cathinones (3-CMC, 4-CMC) follow similar metabolic pathways, suggesting a shared class-level pattern.[22]
Neuroscience[edit]
Neuroscience
Where it acts
3-MMC's primary neural target is the mesolimbic pathway — the reward circuit running from the ventral tegmental area (VTA) to the nucleus accumbens (NAc). Dopamine flooding in this pathway drives the acute euphoria and reinforcement. Animal studies show that 3-MMC at reward-conditioning doses activates the VTA more intensely than methamphetamine,[7] suggesting particularly strong engagement of the brain's reward circuitry. Potent norepinephrine release drives the sympathomimetic effects — elevated heart rate, blood pressure, arousal, and the cognitive performance improvements observed in clinical testing.[5]
Why it matters
The catecholamine-dominant profile creates an asymmetry between "wanting" and "liking" that intensifies with repeated exposure. Controlled data show dose-dependent increases in both drug wanting and liking,[5] but the dopaminergic bias predicts that wanting escalates faster — a pattern characteristic of high-liability stimulants and consistent with the compulsive redosing widely reported by users.[6] Chronic administration selectively weakens inhibitory signaling in the NAc without affecting excitatory transmission,[7] a shift that may tilt the circuit toward compulsive drug-seeking by reducing the brain's ability to brake reward-driven behavior.
Several fundamental questions remain unanswered. Whether 3-MMC produces serotonergic neurotoxicity of the type documented for MDMA and methamphetamine has not been tested. The mechanism behind its demonstrated analgesic effects[13] — whether noradrenergic, serotonergic, or dopaminergic — is uncharacterized.
Subjective Effects[edit]
The 3-MMC experience occupies a middle ground between stimulant drive and empathogenic warmth. At lower oral doses, the stimulant dimension dominates — sharpened focus, physical energy, and information processing enhancement with a clean, functional quality. As dose increases, serotonergic warmth surfaces: sociability deepens, emotional barriers soften, and mild perceptual shifts and dissociative edges appear.[5] Context shapes the balance powerfully — social settings tend to amplify the entactogenic character, while solitary use foregrounds raw stimulation.
Pharmacologically, 3-MMC sits between amphetamine and mephedrone — more stimulant than its para-substituted sibling, less purely empathogenic than MDMA.[5][19] Insufflation compresses the onset and intensifies the dopaminergic rush, amplifying the reinforcing quality but narrowing the entactogenic window.
Effect Grid
At common doses, the full stimulant-entactogenic profile manifests: pronounced euphoria, significantly enhanced energy and motivation, strong sociability and emotional openness, and marked cognitive enhancement — faster processing speed, improved memory, and heightened attention. Empathy and disinhibition become prominent features. Libido enhancement is frequently reported.
Physically, tachycardia and blood pressure elevation are consistent. Jaw clenching, bruxism, and increased sweating are typical. Appetite is strongly suppressed. Mild dissociative or psychotomimetic effects may emerge transiently.
The experience peaks at approximately 1 hour and the primary effects window spans 4–5 hours. Sleep is difficult for several hours after effects subside. Compulsive redosing urges commonly emerge as primary effects begin to wane.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Sound sensitivity · Color enhancement · Visual haze / noise · Tracers · Symmetrical texture repetition · Auditory hallucinations
Symmetrical texture repetition · Auditory hallucinations
Pupil dilation · Excessive sweating · Body high · Heart rate perception changes · Insomnia · Nasal congestion · Physical fatigue · Restlessness · Dry mouth · Tactile euphoria · Dehydration sensation · Muscle tension · Sexual arousal enhancement · Spontaneous body sensations · Nausea · Headache · Bodily lightness · Dizziness · Tingling / electric sensations · Trembling · Vibrations / buzzing · Bruxism · Motor control impairment · Abnormal heartbeat · Sexual arousal suppression · Motor control enhancement · Seizure threshold reduction · Tactile hallucination
Heart rate perception changes · Insomnia · Nasal congestion · Physical fatigue · Restlessness · Dry mouth · Tactile euphoria · Dehydration sensation · Muscle tension · Sexual arousal enhancement · Spontaneous body sensations · Nausea · Headache · Bodily lightness · Dizziness · Tingling / electric sensations · Trembling · Vibrations / buzzing · Bruxism · Abnormal heartbeat · Sexual arousal suppression · Motor control enhancement · Seizure threshold reduction · Tactile hallucination
Motivation suppression · Openness enhancement · Motivation enhancement · Aesthetic enhancement · Focus enhancement · Introspection enhancement · Thought connectivity · Immersion enhancement · Pattern recognition enhancement · Analysis enhancement · Creativity enhancement · Humor enhancement · Information processing enhancement · Thought organization · Thought deceleration
Focus enhancement · Introspection enhancement · Thought connectivity · Immersion enhancement · Pattern recognition enhancement · Analysis enhancement · Creativity enhancement · Humor enhancement · Information processing enhancement · Thought organization · Thought deceleration
Anhedonia · Anxiety · Dysphoria · Emotional enhancement · Anxiety suppression
Anxiety suppression
Communication enhancement · Sociability enhancement · Trust enhancement
Timeline
First alerts emerge as mild stimulation and subtle mood shift. A faint increase in heart rate may be the earliest perceptible signal.
Stimulant effects build steadily: rising energy, increasing sociability, and sharpening focus. Heart rate elevation becomes noticeable. Mild jaw tension may appear.
Maximum stimulant-entactogenic intensity centered around 1 hour post-dose. Euphoria, cognitive enhancement, sociability, and empathy reach their height. Cardiovascular effects are most pronounced.
Effects gradually diminish from peak intensity but remain clearly present. Stimulation and mood elevation continue at reduced levels. Appetite suppression persists.
Stimulant effects fade noticeably. Energy declines, mood returns toward baseline or dips slightly below. Residual jaw tension and mild restlessness may persist.
Residual mild fatigue, subdued mood, and possible irritability. Sleep quality may be reduced even after subjective effects resolve. Appetite returns fully.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 10 days
- Physical
- Low
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- amphetamine · methamphetamine · mephedrone
Toxicity
Acute toxicity
No lethal dose has been established in any species.safety citation needed Acute poisoning presents as stimulant overdose: rapid heart rate, high blood pressure, chest pain, heavy sweating, and agitation.[18] No antidote exists; treatment follows standard stimulant overdose protocols.[10]
27 deaths with confirmed 3-MMC exposure were documented by November 2021,[8] most in polydrug combinations. One fatal case involved a 19-year-old at a blood concentration of 800 ng/mL with no reported co-intoxicants.[19] Another involved approximately 500 mg 3-MMC, 400 mg 5-APB, and 80 g alcohol — progressing from agitation and seizures to cardiovascular collapse within 4 hours.[20]
Liver toxicity
3-MMC damages liver cells in a concentration-dependent way at concentrations relevant to human use.[7] The liver enzymes CYP2D6 and CYP2E1 convert it into toxic metabolites — blocking either enzyme reduced cell death in the laboratory.[7]
Neurotoxicity
Chronic dosing in rats reduced inhibitory signaling in the nucleus accumbens.[6] Whether this is lasting damage or a reversible adaptation is unknown. Standard neurotoxicity assessments — conducted for MDMA and methamphetamine — have not been done for 3-MMC.
Psychological risks
Acute effects include agitation, anxiety, paranoia, and physical restlessness.[18] The controlled trial found mild dissociative and psychosis-like effects at 100 mg oral, resolving without intervention.[4]
The most documented risk is compulsive redosing[5][21] — short duration and strong dopamine reinforcement drive intense urges to take more. Cumulative doses during compulsive sessions can reach ranges associated with severe toxicity. No data on long-term psychiatric consequences have been published.
Tolerance and dependence
No published human tolerance data exist specifically for 3-MMC.[4]
In rats, reward conditioning at 10 mg/kg matched methamphetamine, with VTA activation exceeding it.[6] A systematic review concluded 3-MMC produces more craving, more frequent redosing, and more dependence than mephedrone.[5] Case reports document 3-MMC addiction in chemsex contexts with formal use disorder diagnoses.[21][22][23]
Drug Interactions
The most dangerous documented combination involved approximately 500 mg 3-MMC, 400 mg 5-APB (a potent serotonin releaser), and 80 g alcohol — resulting in fatal cardiovascular collapse within 4 hours.[20] Both 3-MMC and 5-APB flood serotonin pathways; together they likely produced life-threatening overheating on top of stimulant cardiovascular strain.
Combining with MDMA carries similar risk: both release serotonin, and the additive load increases the probability of dangerous overheating and seizures.inferred
MAO inhibitors are theoretically the most dangerous combination — blocking serotonin breakdown while simultaneously flooding the synapse with released serotonin would be expected to cause severe overheating, seizures, and blood pressure crisis.safety citation needed
Combining 3-MMC with GHB or GBL is dangerous because the stimulant masks GHB's sedating effect, allowing dangerously high depressant doses.[22] Multiple chemsex case reports confirm elevated overdose risk in polydrug combinations.[23]
CYP2D6 inhibitors — including fluoxetine, paroxetine, and bupropion — may alter how 3-MMC is cleared, potentially increasing toxicity.[7] Tramadol combined with 3-MMC is flagged in harm reduction databases as potentially lethal — both raise serotonin and lower seizure threshold.safety citation needed
Contraindications
9 knownThe following contraindications follow from 3-MMC's stimulant profile. No substance-specific contraindication studies exist.
Heart conditions: High blood pressure, coronary artery disease, irregular heart rhythm, and structural heart disease. Even doses of 25–100 mg produced measurable cardiovascular stress in the controlled trial.[4]
Liver impairment: Compromised liver function elevates injury risk, given the documented liver toxicity via CYP2D6/CYP2E1 activation.[7]
Serotonergic medications: SSRIs, SNRIs, MAOIs, and other serotonin-releasing agents — additive serotonin burden risks overheating and seizures.
Psychiatric conditions: Psychotic disorders, severe anxiety, or active mania — given the stimulant and psychosis-like properties.
Pregnancy and breastfeeding: No reproductive toxicity data exist. Theoretical risks to fetal development and blood flow apply.inferred
Harm Reduction[edit]
Forms & Identification
3-MMC typically circulates as a white crystalline powder or pressed tablets. It looks similar to other cathinones — 3-CMC, 4-CMC, and mephedrone — and cannot be reliably identified by appearance. Reagent testing narrows the field but cannot distinguish between closely related isomers; only laboratory analysis (GC-MS or FTIR) provides definitive identification. Test every batch regardless of source.
Guidelines
- Test every batch with reagent kits before use — at minimum to rule out dangerous substitutions
- Start with a low oral dose and wait at least 90 minutes before considering redosing — the short duration and rapid offset create strong urges to take more
- Set a firm dose limit before the session begins; compulsive redosing is the most commonly reported loss-of-control pattern with this substance
- Oral administration produces a smoother experience with lower reinforcement than insufflation — nasal dosing intensifies the rush and amplifies compulsive redosing urge
- Keep hydrated but avoid overhydration — drink water at regular intervals without forcing excessive intake
- Eat a light meal several hours before use; stimulants suppress appetite and may prolong recovery if nutrition is neglected
- Avoid use on consecutive days — the catecholamine-depleting mechanism suggests diminishing returns and increased crash severity
- Have a trusted person present who is aware of what was taken and can intervene if behavior becomes compulsive or concerning
Set & Setting
Social environments tend to draw out the empathogenic dimension. Solitary use foregrounds raw stimulation and may intensify compulsive redosing. A familiar, comfortable environment with trusted people provides the safest setting. Avoid crowded venues and hot rooms — stimulant-driven overheating is a real danger.
Aftercare & integration. The stimulant comedown involves catecholamine depletion — expect low mood, fatigue, irritability, and poor concentration in the 24–48 hours after use. Prioritize sleep. Eat nutrient-dense meals even if appetite is suppressed. Light physical activity (walking, stretching) supports recovery better than remaining sedentary.
If low mood persists beyond 3–4 days, or craving to redose become intrusive, speak with a healthcare provider — early intervention is more effective than waiting for patterns to deepen.
Recovery & Support
3-MMC dependence is increasingly recognized in clinical settings, particularly in chemsex contexts. If sessions extend beyond intended limits, dose caps are impossible to keep, or use frequency has increased beyond what was planned — these are early signals of a developing use disorder.
Professional support includes addiction medicine specialists, cognitive behavioral therapy, and peer support groups (SMART Recovery, mutual aid groups). No pharmacological treatment specific to cathinone dependence exists; therapeutic approaches draw on stimulant use disorder frameworks.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Uncomfortable stimulant effects (jaw tension, elevated heart rate, mild anxiety) are distinct from medical emergencies. Seek immediate help for: chest pain or pressure, seizures, loss of consciousness, body temperature hot enough to feel through clothing, severe confusion or paranoia with inability to communicate, or breathing difficulties.
Immediate steps:
- Call emergency services immediately — do not wait to see if symptoms improve
- Move the person to a cool, quiet area
- If conscious, keep them calm and sitting upright; if unconscious, place in the recovery position (on their side, airway clear)
- Do not restrain them unless they pose immediate danger to themselves or others
- Do not induce vomiting
- Remove excess clothing if overheating
What to tell the dispatcher: Name the substance (3-MMC or synthetic cathinone), estimated amount taken, time of ingestion, current symptoms, and whether other substances were involved. Good Samaritan law in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
Legal Status
3-MMC is controlled in most major jurisdictions as of 2026, following EU-wide scheduling in March 2022 and WHO-recommended international Schedule II placement in 2023.[2] Scheduling has pushed users toward less-characterized analogues including 2-MMC and 3-CMC.[5]
Legal status changes frequently and varies by jurisdiction. The information below reflects available data as of 2026 and is not legal advice.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Explicitly listed December 13, 2023; previously covered as mephedrone positional isomer[24] |
| European Union | Controlled (Framework Decision 2004/757/JHA) | EU-wide control since March 18, 2022[8] |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | Covered by generic cathinone ban |
| Netherlands | List 1 Opiumwet (harddrug) | Reclassified from List 2 to List 1 in April 2024[5] |
| Germany | Anlage I BtMG (Schedule I) | Scheduled since December 13, 2014 |
| Poland | Category II-P | Since April 25, 2024 |
| India | Narcotic | Since February 8, 2024 |
| Australia | Illegal | Under synthetic cathinone bans |
| Canada | Illegal | Likely covered as amphetamine analogue under CDSA Schedule Icitation needed |
| International (UN) | Schedule II (Convention on Psychotropic Substances 1971) | WHO ECDD recommended October 2022; adopted March 2023[2] |
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 10 days
- Physical
- Low
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- amphetamine · methamphetamine · mephedrone
Toxicity
Acute toxicity
No lethal dose has been established for 3-MMC in any species.safety citation needed Acute poisoning presents as a stimulant overdose: rapid heart rate, high blood pressure, chest pain, heavy sweating, and agitation.[19] No antidote exists; treatment follows standard stimulant overdose protocols.[11]
The EMCDDA documented 27 deaths with confirmed 3-MMC exposure by November 2021.[9] Most involved polydrug combinations. One fatal case involved a 19-year-old with a blood concentration of 800 ng/mL and no reported co-intoxicants.[17] Another fatality involved approximately 500 mg 3-MMC combined with 400 mg 5-APB and 80 g alcohol, progressing from agitation and seizures to cardiovascular collapse within 4 hours.[23]
In Italy, a statistical correlation has been identified between synthetic cathinone availability and sudden unexpected deaths in young people, though causality cannot be established from ecological data.[24] Dutch Poison Center data show a sharp increase in NPS poisonings among adolescents from 2014 to 2023.[25]
Liver toxicity
3-MMC causes concentration-dependent liver cell damage at concentrations relevant to human use, demonstrated in rat liver cells.[8] The damage cascade involves oxidative stress, mitochondrial disruption, glutathione depletion, and programmed cell death through multiple pathways. The liver enzymes CYP2D6 and CYP2E1 generate the toxic metabolites — blocking either enzyme reduced cell death in the laboratory.[8] Whether CYP2D6 poor metabolizer status confers protection or redirects metabolism toward alternative toxic pathways is unknown.
Neurotoxicity
Chronic dosing in rats reduced inhibitory signaling in the nucleus accumbens without affecting excitatory transmission.[7] Whether this represents lasting brain damage or a reversible adaptation is undefined. Standard neurotoxicity assessments — of the kind conducted for MDMA and methamphetamine — have not been performed for 3-MMC.
Psychological risks
Acute psychological effects include agitation, anxiety, paranoia, and psychomotor restlessness.[19] The controlled trial reported mild dissociative and psychosis-like effects at 100 mg oral that resolved without intervention in the laboratory setting.[5]
Animal data suggest a biphasic anxiety pattern: calming effects at first dose, increased anxiety after 7 days of repeated dosing.[7] The most concerning psychological risk is compulsive redosing — documented across recreational, chemsex, and clinical settings.[6][26] The combination of short duration, strong dopamine reinforcement, and rapid offset creates a profile highly conducive to loss of dosing control within a single session. Cumulative doses during compulsive redosing may reach ranges associated with severe toxicity.
No published data exist on 3-MMC-induced psychosis, persisting perceptual changes, or long-term psychiatric consequences.
Tolerance and dependence
No published human tolerance data exist specifically for 3-MMC. The controlled trial did not assess tolerance development.[5]
Dependence liability is supported by converging evidence. In rats, reward conditioning at 10 mg/kg matched methamphetamine, with ventral tegmental area activation exceeding it.[7] A systematic review concluded that 3-MMC produces "more craving, more frequent re-dosing, and more dependence" than mephedrone.[6] Case reports document 3-MMC addiction in chemsex contexts with formal discussion of diagnostic criteria for 3-MMC use disorder.[26][18][27]
No gold-standard self-administration study — the benchmark for measuring how hard an animal will work to obtain a drug — has been published for 3-MMC.
Drug Interactions
The most dangerous documented combination involved approximately 500 mg 3-MMC with 400 mg 5-APB (a potent serotonin releaser) and 80 g alcohol, resulting in fatal cardiovascular collapse within 4 hours.[23] The combined serotonin release from both compounds likely produced serotonin syndrome superimposed on stimulant cardiovascular strain.
Combination with MDMA carries analogous risk: both release serotonin, and additive effects increase the probability of serotonin syndrome and dangerous overheating. inferred
Monoamine oxidase inhibitors represent the highest theoretical danger — blocking serotonin breakdown while simultaneously flooding the synapse with released serotonin would be expected to produce severe serotonin syndrome and blood pressure crisis. safety citation needed
A severe non-fatal intoxication involved combined 3-MMC and GHB use in a chemsex setting (blood 3-MMC 177 ng/mL, GHB 131 mg/L).[18] The stimulant masks GHB sedation, allowing dangerously high depressant doses. Multiple chemsex case reports document 3-MMC combined with GHB/GBL, ketamine, and other substances; polydrug combinations substantially increase overdose risk.[27]
Alcohol was present in the first published fatal case alongside 5-APB,[23] but its independent contribution to the fatal outcome cannot be determined from a single polydrug case.
The involvement of CYP2D6 in 3-MMC metabolism[8] raises interaction potential with potent CYP2D6 inhibitors (certain SSRIs including fluoxetine and paroxetine, bupropion, quinidine). These agents could alter 3-MMC clearance or redirect metabolism toward alternative pathways. No pharmacokinetic interaction data exist.
Tramadol combined with 3-MMC is flagged in community harm reduction databases as potentially lethal.safety citation needed The mechanistic basis includes additive serotonin activity and combined seizure threshold reduction.
Contraindications
9 knownThe following contraindications follow from 3-MMC's profile as a potent stimulant that forces catecholamine release. No substance-specific contraindication studies have been published.
Heart conditions: High blood pressure, coronary artery disease, irregular heart rhythm, and structural heart disease. Even modest doses of 25–100 mg produced measurable cardiovascular stress in the controlled trial.[5]
Liver impairment: The documented liver toxicity via CYP2D6/CYP2E1 metabolic activation[8] means compromised liver function elevates injury risk.
Serotonergic medications: SSRIs, SNRIs, MAOIs, and other serotonin-releasing agents — additive serotonin burden risks serotonin syndrome.
Psychiatric conditions: Psychotic disorders, severe anxiety disorders, or active mania — given the stimulant and psychosis-like properties.
Pregnancy and breastfeeding: No reproductive toxicity data exist. As a potent stimulant monoamine releaser, theoretical risks to fetal development and blood flow to the placenta apply. inferred
Harm Reduction[edit]
Forms & Identification
3-MMC typically circulates as a white crystalline powder or pressed tablets. The visual similarity to other cathinones — particularly 3-CMC, 4-CMC, and mephedrone — makes identification by appearance alone unreliable. Reagent testing narrows the field but cannot distinguish between closely related cathinone isomers; only laboratory-grade analysis (GC-MS or FTIR) provides definitive identification. Given that supply chains have shifted between manufacturing countries and purity varies between batches, testing every batch matters more than trusting a source.
Guidelines
- Test every batch with reagent kits before use — at minimum, to rule out dangerous substitutions
- Start with a low oral dose and wait at least 90 minutes before considering redosing — the short duration and rapid offset create strong urges to take more
- Set a firm dose limit before the session begins; compulsive redosing is the most commonly reported loss-of-control pattern with this substance
- Oral administration produces a smoother experience with lower reinforcement than insufflation — nasal dosing intensifies the rush and amplifies compulsive redosing urge
- Keep hydrated but avoid overhydration — drink water at regular intervals without forcing excessive intake
- Eat a light meal several hours before use; stimulants suppress appetite and may prolong recovery if nutrition is neglected
- Avoid use on consecutive days — the catecholamine-depleting mechanism suggests diminishing returns and increased crash severity with repeated sessions
- Have a trusted person present who is aware of what was taken and can intervene if behavior becomes compulsive or concerning
Set & Setting
The balance between 3-MMC's stimulant and entactogenic dimensions shifts considerably with environment. Social settings tend to draw out empathogenic warmth; solitary use foregrounds raw stimulation and may intensify compulsive redosing. A familiar, comfortable environment with trusted people provides the safest context. Avoid environments where overheating risk is elevated — crowded venues, hot rooms — as stimulant-driven hyperthermia compounds the danger.
Aftercare & integration. The stimulant comedown from 3-MMC involves catecholamine depletion — expect low mood, fatigue, irritability, and poor concentration in the 24–48 hours following use. Prioritize sleep: use blackout curtains, avoid screens, and consider magnesium supplementation if jaw tension or muscle tightness persists.
Eat nutrient-dense meals even if appetite is suppressed. Hydrate steadily. Light physical activity (walking, stretching) supports recovery better than remaining sedentary. If low mood persists beyond 3–4 days, or if cravings to redose become intrusive, consider speaking with a healthcare provider — early intervention is more effective than waiting for patterns to entrench.
Recovery & Support
3-MMC dependence is increasingly recognized in clinical settings, particularly in chemsex contexts. If use has become compulsive — sessions extending beyond intended limits, inability to keep to a dose cap, using more frequently than planned — these are early signals of a developing use disorder.
Professional support options include addiction medicine specialists, cognitive behavioral therapy, and peer support groups (SMART Recovery, mutual aid groups). In the Netherlands, treatment-seeking for 3-MMC dependence has increased measurably. No pharmacological treatment specific to cathinone dependence exists; therapeutic approaches draw on stimulant use disorder frameworks.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Uncomfortable stimulant effects (jaw tension, elevated heart rate, mild anxiety) are distinct from medical emergencies. Seek immediate help for: chest pain or pressure, seizures, loss of consciousness, body temperature hot enough to feel through clothing, severe confusion or paranoia with inability to communicate, or breathing difficulties.
Immediate steps:
- Call emergency services immediately — do not wait to see if symptoms improve
- Move the person to a cool, quiet area
- If conscious, keep them calm and sitting upright; if unconscious, place in the recovery position (on their side, airway clear)
- Do not restrain them unless they pose immediate danger to themselves or others
- Do not induce vomiting
- Remove excess clothing if overheating
What to tell the dispatcher: Name the substance (3-MMC or synthetic cathinone), estimated amount taken, time of ingestion, current symptoms, and whether other substances were involved. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
Legal Status
3-MMC is controlled in most major jurisdictions as of 2026. The EMCDDA's November 2021 risk assessment documented 27 deaths and life-threatening consequences,[9] prompting EU-wide control in March 2022. The WHO recommended Schedule II placement under the Convention on Psychotropic Substances in 2023,[3] making 3-MMC subject to international scheduling obligations.
The regulatory trajectory illustrates a recurring pattern: scheduling may curb one substance's spread while driving users toward less-characterized alternatives. Users are already transitioning to analogues including 2-MMC and 3-CMC.[6]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Explicitly listed December 13, 2023; previously covered as mephedrone positional isomer[28] |
| European Union | Controlled (Framework Decision 2004/757/JHA) | EU-wide control since March 18, 2022[9] |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | Covered by generic cathinone ban |
| Netherlands | List 1 Opiumwet (harddrug) | Reclassified from List 2 to List 1 in April 2024[6] |
| Germany | Anlage I BtMG (Schedule I) | Scheduled since December 13, 2014 |
| Poland | Category II-P | Since April 25, 2024 |
| India | Narcotic | Since February 8, 2024 |
| Australia | Illegal | Under synthetic cathinone bans |
| Canada | Illegal | Likely covered as amphetamine analogue under CDSA Schedule Icitation needed |
| International (UN) | Schedule II (Convention on Psychotropic Substances 1971) | WHO ECDD recommended October 2022; adopted March 2023[3] |
Frequently asked questions
What is 3-MMC?
3-MMC is a synthetic substituted cathinone with stimulant and entactogenic properties, first identified on the European drug market in 2012. It acts as a catecholamine-preferring triple monoamine releasing agent (DAT:SERT ratio ~9.6) and is internationally scheduled under UN Schedule II.
How long does 3-MMC last?
Total duration by route of administration — Oral: 4 – 6 hours; Insufflated: 2.5 – 4.5 hours; Intravenous: 2 – 4 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for 3-MMC?
Psychedex publishes a dosage table for 3-MMC on this page covering these routes of administration: insufflated, intravenous, oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with 3-MMC?
The highest-severity documented interactions for 3-MMC: MAOIs (Lethal), 5-HTP, Tryptophan (Dangerous), Alpha-2 adrenergic receptor antagonist (Dangerous), Anticholinergics (Dangerous), Antihistamines (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is 3-MMC addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for 3-MMC: tolerance builds moderate; full reset takes 10 days; cross-tolerance develops with amphetamine, methamphetamine, mephedrone, cocaine, methylphenidate, MDMA. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1]
- [2]
- [3] ^abSalgueiro-Gonzalez N, Béen F, Bijlsma L, Boogaerts T, Covaci A, et al. (2024) Influent wastewater analysis to investigate emerging trends of new psychoactive substances use in Europe — Water research doi:10.1016/j.watres.2024.121390
- [4]
- [5]
- [6]
references
- [1] ^abSimmler LD, Buser TA, Donzelli M, et al. (2012) Pharmacological characterization of designer cathinones in vitro — British Journal of Pharmacology doi:10.1111/j.1476-5381.2012.02145.x
- [2]
- [3]
- [4] ^abSalgueiro-Gonzalez N, Béen F, Bijlsma L, Boogaerts T, Covaci A, et al. (2024) Influent wastewater analysis to investigate emerging trends of new psychoactive substances use in Europe — Water research doi:10.1016/j.watres.2024.121390
- [5]
- [6]